Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.20 USD

201.20
7,194,067

-0.48 (-0.24%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $201.20 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed at $148.25 in the latest trading session, marking a -0.54% move from the prior day.

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs

The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Zacks Analyst Blog Highlights Oracle, AbbVie, Lowe's Companies, Ecolab and Motorola Solutions

Oracle, AbbVie, Lowe's Companies, Ecolab and Motorola Solutions are part of the Zacks top Analyst Blog .

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

Smart Beta ETF report for DHS

Sheraz Mian headshot

Top Analyst Reports for Oracle, AbbVie & Lowe's

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), AbbVie Inc. (ABBV) and Lowe's Companies, Inc. (LOW).

Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL

Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $154.65 in the latest trading session, marking a +1.25% move from the prior day.

Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?

Style Box ETF report for DHS

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $153.94, marking a +1.2% move from the previous day.

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More

The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.

Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?

Style Box ETF report for SDY

Zacks Investment Ideas feature highlights: Novo Nordisk, Eli Lilly and AbbVie

Novo Nordisk, Eli Lilly and AbbVie have been highlighted in this Investment Ideas article.

Andrew Rocco headshot

"Blockbuster Status": 3 Bios to Buy and Hold

The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.

AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals

AbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week 24 and superiority of endoscopic remission at week 48 versus J&J's Stelara in a head-to-head study.

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed at $149.04 in the latest trading session, marking a +0.01% move from the prior day.

Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study

Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed at $146.10 in the latest trading session, marking a -1.42% move from the prior day.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?

Smart Beta ETF report for SDY

Kinjel Shah headshot

Pharma Stock Roundup: J&J's New '23 View After Kenvue Separation, Regulatory Updates

J&J (JNJ) updates its financial guidance for 2023 after the final separation of Kenvue. Pfizer, BioNTech, Merck and AbbVie announce regulatory developments.